UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 189

Sortiert nach

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

Leukemia, 2013-02, Vol.27 (2), p.430-440

2013

Volltextzugriff (PDF)

The skinny on obesity and plasma cell myeloma: a review of the literature

Bone marrow transplantation (Basingstoke), 2014-08, Vol.49 (8), p.1009-1015

2014

Volltextzugriff (PDF)

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma

Leukemia, 2017-07, Vol.31 (7), p.1648-1650

2017

Volltextzugriff (PDF)

Postoperative nausea and vomiting at Landspitali: A prospective study

Acta anaesthesiologica Scandinavica, 2024-04, Vol.68 (4), p.457-465

2024

Volltextzugriff (PDF)

Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma

Leukemia & lymphoma, 2015-03, Vol.56 (3), p.615-621

2015

Volltextzugriff (PDF)

Postoperative pain at Landspitali: A prospective study

Acta anaesthesiologica Scandinavica, 2024-07, Vol.68 (6), p.830-838

2024

Volltextzugriff (PDF)

Breast cancer-derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment

The Journal of clinical investigation, 2021-10, Vol.131 (20), p.1-17

2021

Volltextzugriff (PDF)

ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MAGNETISMM-3 STUDY

Hematology, Transfusion and Cell Therapy, 2023-10, Vol.45, p.S404-S405

2023

Volltextzugriff (PDF)

P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T‐CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

HemaSphere, 2022-06, Vol.6 (Suppl), p.788-789

2022

Volltextzugriff (PDF)

Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study

Bone marrow transplantation (Basingstoke), 2009-05, Vol.43 (10), p.793-800

2009

Volltextzugriff (PDF)

An Activated Receptor Tyrosine Kinase, TEL/PDGFβR, Cooperates with AML1/ETO to Induce Acute Myeloid Leukemia in Mice

Proceedings of the National Academy of Sciences - PNAS, 2003-08, Vol.100 (16), p.9506-9511

2003

Volltextzugriff (PDF)

Multifrequency studies of massive cores with complex spatial and kinematic structures

Astronomy reports, 2016-10, Vol.60 (10), p.904-923

2016

Volltextzugriff (PDF)

A Murine Model of CML Blast Crisis Induced by Cooperation between BCR/ABL and NUP98/HOXA9

Proceedings of the National Academy of Sciences - PNAS, 2002-05, Vol.99 (11), p.7622-7627

2002

Volltextzugriff (PDF)

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM‐3

HemaSphere, 2022-06, Vol.6 (Suppl), p.839-840

2022

Volltextzugriff (PDF)

Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes

The EMBO journal, 1998-09, Vol.17 (18), p.5321-5333

1998

Volltextzugriff (PDF)

The TEL/Platelet-Derived Growth Factor β Receptor (PDGFβ R) Fusion in Chronic Myelomonocytic Leukemia is a Transforming Protein that Self-Associates and Activates PDGFβ R Kinase-Dependent Signaling Pathways

Proceedings of the National Academy of Sciences - PNAS, 1996-12, Vol.93 (25), p.14845-14850

1996

Volltextzugriff (PDF)

Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia

The Journal of clinical investigation, 2010-06, Vol.120 (6), p.2109-2118

2010

Volltextzugriff (PDF)

EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Hematology, Transfusion and Cell Therapy, 2021-10, Vol.43, p.S195-S196

2021

Volltextzugriff (PDF)

Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes

Bone marrow transplantation (Basingstoke), 2004-10, Vol.34 (7), p.615-619

2004

Volltextzugriff (PDF)

Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL

Blood, 2001-03, Vol.97 (5), p.1442-1450

2001

Volltextzugriff (PDF)

Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience

Blood, 2018-11, Vol.132 (Supplement 1), p.2152-2152

2018

Volltextzugriff (PDF)

Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone

Bone marrow transplantation (Basingstoke), 2005-09, Vol.36 (6), p.531-538

2005

Volltextzugriff (PDF)

Intrinsic Human Immunodeficiency Virus Type 1 Resistance of Hematopoietic Stem Cells Despite Coreceptor Expression

Journal of Virology, 1999-01, Vol.73 (1), p.728-737

1999

Volltextzugriff (PDF)

c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations

Blood, 2005-10, Vol.106 (7), p.2452-2461

2005

Volltextzugriff (PDF)

TEL/PDGFβR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor

Blood, 1999-03, Vol.93 (5), p.1707-1714

1999

Volltextzugriff (PDF)

1 – 25 von 189

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(173)
Mit Volltextzugriff
(179)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(92)
Life Sciences & Biomedicine
(81)
Humans
(65)
Female
(38)
Male
(36)
Biological And Medical Sciences
(30)
Medical Sciences
(28)
Adult
(27)
Middle Aged
(25)
Animals
(23)
Hematology
(22)
Aged
(21)
Mice
(19)
Oncology
(19)
Multiple Myeloma
(16)
Bone Marrow
(13)
Mutation
(13)
Hematologic And Hematopoietic Diseases
(12)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(12)
Risk Factors
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

The skinny on obesity and plasma cell myeloma: a review of the literature

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma

Postoperative nausea and vomiting at Landspitali: A prospective study

Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma

Postoperative pain at Landspitali: A prospective study

Breast cancer-derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment

ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MAGNETISMM-3 STUDY

P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T‐CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study

An Activated Receptor Tyrosine Kinase, TEL/PDGFβR, Cooperates with AML1/ETO to Induce Acute Myeloid Leukemia in Mice

Multifrequency studies of massive cores with complex spatial and kinematic structures

A Murine Model of CML Blast Crisis Induced by Cooperation between BCR/ABL and NUP98/HOXA9

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM‐3

Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes

The TEL/Platelet-Derived Growth Factor β Receptor (PDGFβ R) Fusion in Chronic Myelomonocytic Leukemia is a Transforming Protein that Self-Associates and Activates PDGFβ R Kinase-Dependent Signaling Pathways

Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia

EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes

Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL

Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience

Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone

Intrinsic Human Immunodeficiency Virus Type 1 Resistance of Hematopoietic Stem Cells Despite Coreceptor Expression

c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations

TEL/PDGFβR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor

Suchergebnisse filtern